Genmab A/S (Nasdaq: GMAB; 0MGB), the Copenhagen-headquartered international biotechnology company, has announced that 22 abstracts evaluating epcoritamab will be presented at the 68th Annual Meeting of the American Society of Hematology (ASH), taking place 12–15 December 2026 in New Orleans, Louisiana. The data package includes six oral presentations, among them the first disclosure of primary results from the Phase 3 EPCORE DLBCL-4 study evaluating epcoritamab in combination with lenalidomide in relapsed or refractory diffuse large B-cell lymphoma. Investors are watching this readout closely as it represents a pivotal dataset for a therapy already approved in more than 65 countries.

Key Points

  • Genmab A/S (Nasdaq: GMAB; 0MGB) issued the announcement on 4 November 2026
  • 22 abstracts evaluating epcoritamab accepted for ASH 2026, including six oral presentations
  • Primary results from Phase 3 EPCORE DLBCL-4 to be presented on 14 December 2026; Genmab R&D update scheduled for 16 December 2026
  • Investors should watch the EPCORE DLBCL-4 readout and updated EPCORE FL-1 subgroup analyses for clinical and commercial implications

Phase 3 EPCORE DLBCL-4 Primary Results to Headline Genmab's ASH 2026 Presence

The most closely anticipated presentation is abstract 919, an oral presentation on 14 December 2026 disclosing primary results from the Phase 3 EPCORE DLBCL-4 study. This trial compares fixed-duration epcoritamab plus lenalidomide against rituximab plus gemcitabine and oxaliplatin in patients with relapsed or refractory DLBCL. The results have also been selected for the ASH 2026 Press Program, indicating their significance to the broader haematology community. The announcement notes that the safety and efficacy of epcoritamab have not been established for these investigational uses, underscoring the trial's status as ongoing research.

Epcoritamab's Subcutaneous Bispecific Mechanism and Global Regulatory Footprint

Epcoritamab is an IgG1-bispecific antibody created using Genmab's proprietary DuoBody technology and is administered subcutaneously. It is designed to simultaneously bind CD3 on T cells and CD20 on B cells, inducing T-cell-mediated killing of CD20-positive malignant cells. The therapy has received regulatory approval in certain lymphoma indications in more than 65 countries, marketed as EPKINLY in the United States and Japan and as TEPKINLY in the European Union. It is co-developed with AbbVie, with both companies sharing commercial responsibilities in the US and Japan.

Broad Data Programme Spans Follicular Lymphoma, CLL, and Real-World Evidence

Beyond DLBCL-4, the ASH programme includes updated subgroup analyses from the Phase 3 EPCORE FL-1 study in relapsed or refractory follicular lymphoma, 33-month follow-up data from EPCORE NHL-5 evaluating epcoritamab plus pola-R-CHP in first-line DLBCL, and first results from the EPCORE CLL-1 trial in relapsed or refractory chronic lymphocytic leukaemia. Real-world effectiveness data and health economic analyses, including a US cost-effectiveness evaluation, are also included, further informing epcoritamab's evolving clinical and commercial profile across B-cell malignancies.

Genmab R&D Update Scheduled for 16 December 2026 Following ASH Meeting

Genmab will host a virtual 2026 R&D Update and ASH Data Review on 16 December 2026 at 10:30 AM EST, the day after the main conference concludes. The event will be webcast live, with registration details to be published on genmab.com. Late-breaking ASH abstracts are due to be posted online on 7 December 2026 at 9:00 AM EST. Investors monitoring the breadth of Genmab's pipeline across bispecific antibodies, antibody-drug conjugates, and other next-generation modalities may treat both events as near-term catalysts for assessing the company's clinical progress.